MedTrace Logo

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

NCT03764241 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2023-06-01

No results posted yet for this study

Summary

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the treatment of post-STEMI left ventricular thrombus.

Conditions

  • ST Segment Elevation Myocardial Infarction
  • Left Ventricular Thrombus

Interventions

DRUG

Rivaroxaban

Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.

DRUG

Vitamin K Antagonist

warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • Shanghai Minhang Central Hospital

    collaborator OTHER

  • Shanghai Songjiang Central Hospital

    collaborator UNKNOWN

  • Shanghai Fengxian District Central Hospital

    collaborator OTHER

  • Zhoushan Hospital in Zhejiang Province

    collaborator UNKNOWN

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-03-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03764241 on ClinicalTrials.gov